Search Results

What Brent Saunders Thinks About a Possible Allerg

Deals

Botox Maker Allergan Buys Aesthetic Company Bonti for $195 Million Up Front

Dublin-based Allergan is acquiring Newport Beach, California-based Bonti with an upfront payment of $195 million.

September 14, 2018

·

3 min read

·

Mark Terry

Business

Bonti Appoints Dr. Jacob Chacko to Board of Directors

Bonti today announced the appointment of Dr. Jacob Chacko to its Board of Directors, effective immediately.

February 12, 2018

·

2 min read

Drug Development

Bonti Announces Successful Completion of Phase 2a Scar Reduction Clinical Study

Bonti today announced the topline results of its SHINE-1 Phase 2a clinical trial.

August 2, 2018

·

5 min read

Deals

Allergan to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics Pipeline

Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced it has agreed to acquire Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications.

September 14, 2018

·

4 min read

Business

Bonti Announces Close of $15.5 Million Series C Funding and Appointment of David Ramsay as Chief Financial Officer

Bonti announced it successfully closed a $15.5 million Series C financing, bringing the cumulative investment in the Company to over $36 million.

January 23, 2018

·

4 min read

Drug Development

Bonti Announces Dosing of the First Patient in the SHINE-1 Phase II Clinical Study Evaluating EB-001 for Scar Reduction

Bonti announced the initiation of the SHINE (Scar Healing Improvement with Neurotoxin E) clinical program, aimed at scar reduction using its novel neurotoxin.

February 8, 2018

·

4 min read

Drug Development

Bonti Announces Presentation Featuring EB-001A at Masters of Aesthetics Symposium

Dr. Jean Carruthers to Highlight Key Aesthetic Clinical Study Results for This Novel Neurotoxin with a Unique Clinical Profile

August 23, 2018

·

3 min read

Biotech Beach

Bonti Announces Hot Topics Presentation Featuring EB-001 At Plastic Surgery The Meeting

October 9, 2017

·

4 min read

Drug Development

Bonti Announces Start of LANTERN-2 Phase 2 Clinical Trial Evaluating EB-001T in Treating Focal Muscle Pain

Program aimed at treating focal muscle pain and reducing use of rescue medications, including opioids.

May 9, 2018

·

5 min read

Drug Development

Bonti Announces Topline Results Of EB-001 Phase IIA Clinical Study In Glabellar Lines

August 10, 2017

·

5 min read